Promising Breakthrough in the Treatment of Onchocerciasis
Scientists are exploring a potential breakthrough in the treatment of onchocerciasis, a debilitating disease caused by parasitic worms. This innovative approach involves utilizing a commonly available antibiotic that is distributed worldwide under various brand names. By targeting and eradicating the Wolbachia bacteria, which the adult worms depend on for survival, this treatment effectively eliminates the worms as well. In some cases, a combination therapy approach is employed, aiming to tackle both the bacteria and the worms simultaneously. However, it is important to note that caution should be exercised when prescribing this medication to individuals with Loa loa, another parasitic infection.
Risk Factors for Onchocerciasis
Onchocerciasis is most commonly found in tropical climates, primarily in approximately 30 sub-Saharan countries in Africa. However, it can also occur in other regions such as the Americas, Yemen, and the Middle East. While the spread of the parasite is not as severe in the Americas, the government no longer actively works to prevent transmissions, except for specific areas in Venezuela and Brazil. Out of the 20 to 25 million individuals worldwide who are infected with onchocerciasis, around 300,000 suffer from blindness, and 800,000 have some form of visual impairment. An estimated 123 million people globally are at risk of contracting an O. volvulus infection.